Arbutus Biopharma Corporation (ABUS)

NASDAQ: ABUS · USD

$4.33

+0.04 (+0.8%)· Recorded snapshot

Market cap	855.7M
Revenue (ttm)	181.7M
Net income (ttm)	153.1M
EPS (ttm)	$0.79
Shares out	197.8M
P/E (trailing)	5.5x
Volume	1,013,646
Beta	0.76

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 181.7M
Net income (ttm): 153.1M
EPS (ttm): $0.79
P/E (trailing): 5.5x
Market cap: 855.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	نگه‌داری

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E5.5

P25 n/aP50 n/aP75 n/a

ROE89.6

P25 n/aP50 n/aP75 n/a

ROIC52.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ABUS indicators

Market & fundamental data

Available fields

215

Groups with data

Currency

USD

Showing 215 of 215 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001447028
Company name	Arbutus Biopharma Corporation
Country	United States
Country code	US
CUSIP number	03879J100
Earnings date	2026-11-12
Earnings time	bmo
Employees	19
Employees change	-25
Employees growth	-56.82%
Enterprise value	$766.7M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2005
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	CA03879J1003
Last 10-K release date	2026-03-23
Last earnings date	2026-08-12
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$855.7M
Market cap category	Small-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$4.33
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ABUS
U.S. state	Pennsylvania
Website	https://www.arbutusbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	18.26%
EV/Earnings	4.94x
EV/EBIT	5.13x
EV/EBITDA	5.13x
EV/Sales	4.16x
FCF / EV yield	-3.25%
FCF yield	-2.91%
Forward EV/Sales	187x
Forward P/S	208.99x
Graham number	4.82257
Graham upside	12.81%
P/B ratio	3.28x
P/E ratio	5.48x
P/S ratio	4.65x
Price / tangible book value	3.27x
Price/EBITDA ratio	5.74x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	81.13%
EBITDA margin	81.15%
Gross margin	90.2%
Operating margin	81.13%
Pretax margin	84.23%
Profit margin	84.23%
Profit per employee	$8.1M
Revenue per employee	$9.6M
ROA	48.84%
ROA (5Y)	-24.26%
ROCE	54.47%
ROE	89.58%
ROE (5Y)	-53.76%
ROIC	52.6%
SBC / revenue	3.03%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	6
Net income growth years	2
Revenue growth	1,078.78%
Revenue growth (Q)	-90.56%
Revenue growth (QoQ)	-99.43%
Revenue growth 10Y	26.25%
Revenue growth 3Y	97.65%
Revenue growth 5Y	85.15%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$44,000
EBIT	$147.4M
EBITDA	$147.5M
EPS	$0.79
FCF per share	$-0.12
Financing cash flow	$17.3M
Free cash flow	$-24.6M
Free cash flow minus SBC	$-30.1M
Gross profit	$163.9M
Investing cash flow	$-10.8M
Net cash flow	$-18.2M
Net income	$153.1M
Operating cash flow minus SBC	$-30.1M
Operating income	$147.4M
Revenue	$181.7M
Stock-based compensation	$5.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	29.51
Book value per share	$1.31
Debt / EBITDA	0.02
Debt / equity	0.01
Interest coverage	1,939.86
Long-term assets	$142,000
Long-term liabilities	$11.9M
Net cash (debt)	$89M
Net cash / market cap	10.52%
Net cash growth	-4.39%
Net debt / EBITDA	-0.6
Net debt / equity	-0.34
Piotroski F-Score	6
Property, plant and equipment	$10,000
Shareholders' equity	$258.7M
Tangible book value	$258.7M
Tangible book value per share	$1.31
Total assets	$274M
Total cash	$92.6M
Total debt	$3.6M
Total liabilities	$15.3M
WACC	8.41%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.96
Current assets	$273.9M
Current liabilities	$3.4M
Current ratio	81.42
Net working capital	$178.4M
Quick ratio	81.08
Working capital	$270.5M
Working capital turnover	0.99

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.21%
Dividend yield	0%
Shareholder yield	-2.21%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	35.16%
10Y return CAGR	3.06%
10Y total return	35.16%
150-day SMA	$4.56
15Y price change	154.41%
15Y return CAGR	6.42%
15Y total return	154.41%
1D price change	0.82%
1M price change	-10.82%
1M total return	-10.82%
1W price change	3.47%
1W total return	3.47%
1Y price change	-3.24%
1Y return CAGR	-3.25%
1Y total return	-3.24%
20-day SMA	$4.29
200-day SMA	$4.50
3M price change	-1.93%
3M total return	-1.93%
3Y price change	150%
3Y return CAGR	35.71%
3Y total return	150%
50-day SMA	$4.74
50-day SMA vs 200-day SMA	50over200
52-week high	$5.45
52-week high date	2026-08-21
52-week low	$3.50
52-week low date	2026-02-02
5Y price change	6.27%
5Y return CAGR	1.22%
5Y total return	6.27%
6M price change	1.05%
6M total return	1.05%
All-time high	$31.48
All-time high date	2014-03-13
All-time low	$0.82
All-time low date	2019-10-21
Average true range (ATR)	$0.14
Average volume	4.2M
Beta (1Y)	1.07
Beta (2Y)	0.53
Beta (5Y)	0.76
Change from 52-week high	-20.64%
Change from 52-week low	23.57%
Change from all-time high	-86.26%
Change from all-time low	426.54%
Change from open	1.53%
Day's gap	-0.7%
Dollar volume	$4.4M
High price	$4.33
Low price	$4.26
Monthly RSI	52.62
Open price	$4.26
Position in 52-week range	100%
Premarket change	0.46%
Premarket close	$4.29
Premarket price	$4.31
Premarket volume	126.8K
Previous close	$4.29
Price vs 150-day SMA	-5.15%
Price vs 20-day SMA	0.84%
Price vs 200-day SMA	-3.91%
Price vs 50-day SMA	-8.74%
Relative volume	0.25
RSI	45.11
Sharpe ratio	0.07
Sharpe ratio (3Y)	0.84
Sharpe ratio (5Y)	0.2
Sortino ratio	0.21
Sortino ratio (3Y)	1.43
Sortino ratio (5Y)	0.43
Volume	1M
Weekly RSI	45.4
YTD price change	-10.08%
YTD total return	-10.08%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	150.5M
Float percentage	76.09%
Shares change (QoQ)	1.16%
Shares change (YoY)	2.21%
Shares held by insiders	0.83%
Shares held by institutions	58.75%
Shares outstanding	197.8M
Short % of float	16.32%
Short % of shares	12.42%
Short ratio	5 days

Deeper analysis on ABUS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ABUS report

Is a complete ABUS research report available?

No complete published report is available for Arbutus Biopharma Corporation (ABUS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Arbutus Biopharma Corporation (ABUS)

Price

Financial snapshot

Fair-value bridge

Latest news · ABUS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ABUS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ABUS

Frequently asked questions